NDC product
Chlordiazepoxide Hydrochloride and Clidinium Bromide
NDC 11534-197 · Sunrise Pharmaceutical, Inc.
Key facts
| Product NDC | 11534-197 |
|---|---|
| Proprietary name | Chlordiazepoxide Hydrochloride and Clidinium Bromide |
| Nonproprietary name | Chlordiazepoxide Hydrochloride and Clidinium Bromide |
| Substances | CHLORDIAZEPOXIDE HYDROCHLORIDE, CLIDINIUM BROMIDE |
| Dosage form | CAPSULE |
| Route | ORAL |
| Labeler | Sunrise Pharmaceutical, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA211421 |
| DEA schedule | CIV |
| Pharmacologic classes | Anticholinergic [EPC], Benzodiazepine [EPC], Benzodiazepines [CS], Cholinergic Antagonists [MoA], Decreased Parasympathetic Acetylcholine Activity [PE], Digestive/GI System Activity Alteration [PE] and 1 more |
| Marketing start | Jul 9, 2020 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: